Features | Partner Sites | Information | LinkXpress
Sign In
AB Sciex
RANDOX LABORATORIES
FOCUS DIAGNOSTICS, INC.

Advanced Blood Test Detects and Analyzes Circulating Tumor Cells

By Labmedica International staff writers
Posted on 13 Feb 2012
An advanced blood test detects and analyzes circulating tumor cells (CTCs) from cancer patients.

The new test, called high definition CTC (HD-CTC), labels cells in a patient's blood sample in a way that distinguishes possible CTCs from ordinary red and white blood cells. A digital microscope and an image-processing algorithm are used to isolate the suspect cells with sizes and shapes (morphologies) unlike those of healthy cells. A pathologist can examine the images of the suspected CTCs to eliminate false positives and note their morphologies.

Scientists from The Scripps Research Institute (TSRI; La Jolla, CA, USA), Scripps Health, and collaborating cancer physicians successfully demonstrated the effectiveness of the blood test. Five new studies resulted from the collaboration and demonstrated the new test's accuracy and effectiveness for a number of different cancer types. The studies also began to explore the utility of the technology for diagnosing and monitoring patients and improving cancer research in the lab.

"It is a next-generation technology," said Scripps' Associate Prof. Peter Kuhn, PhD, senior investigator of the new studies and primary inventor of the high-definition blood test. "It significantly boosts our ability to monitor, predict, and understand cancer progression, including metastasis, which is the major cause of death for cancer patients."

Whereas other tests for CTCs typically use enrichment steps in which suspected CTCs are concentrated--methods that can inadvertently exclude some types of CTCs--the new studies show HD-CTC works well as a no-cell-left-behind process and enables a more complete analysis.

Prof. Kuhn emphasized that the basic setup can be easily modified with different cell-labeling and image-processing techniques. He and his colleagues will study the use of HD-CTC as a potential screening test and develop it further for use in clinical monitoring and cancer research. Prof. Kuhn has founded a San Diego-based biotechnology company, Epic Sciences, Inc. (CA, USA) to develop HD-CTC commercially for companion diagnostic products in personalized cancer care.

The studies were published in the February 2012 edition of the journal Physical Biology.

Related Links:
The Scripps Research Institute
Epic Sciences



ADVANCED INSTRUMENTS
DiagCor Bioscience
VIRCELL
comments powered by Disqus
Life Technologies

Channels

Genetic Tests

view channel

Next Generation Sequencing Reveals Genetic Basis for Congenital Cataracts

Applying the latest high-throughput, next-generation DNA sequencing technology has enabled researchers in the United Kingdom to diagnose children with rare diseases that are characterized by the formation of congenital cataracts. Diagnosing which of the more than 100 diseases that cause between 20,000 and 40,000 cases... Read more

Immunology

view channel
Image: The fluorescence-activated cell sorting FACSCanto II flow cytometer (Photo courtesy of BD Biosystems).

Flow Cytometry Detects Lymphoproliferative Disorders in Fluid Specimens

Immunophenotypic analysis of hematopoietic cell populations by flow cytometry has emerged as a useful ancillary study in the diagnostic evaluation of serous effusions and cerebrospinal fluids (CSFs).... Read more

Lab Tech.

view channel
Image: A technical breakthrough for DNA imaging has been achieved that should quicken diagnosis of diseases for which analysis of DNA from single-cells is critical, such as early stage cancers and various pre-natal conditions (Photo courtesy of McGill University and Génome Québec Innovation Center).

Breakthrough DNA Analysis Technology to Hasten Problem Diagnosis

Researchers have achieved a technical breakthrough that should result in speedier diagnosis of diseases for which analysis of DNA from single-cells is critical, such as early stage cancers and various... Read more

Industry News

view channel

Most IVD Sector Companies Look Outside the EU and USA for Growth

Kalorama Information (New York City, NY, USA) has now published the 9th edition of its biennial market research report “Worldwide Market for In Vitro Diagnostics,” revealing estimates from its survey of the in vitro diagnostics (IVD) industry – presenting the trends, technologies, customer needs, and major suppliers with... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.